Coexistence of benign phyllodes tumor and invasive ductal carcinoma in distinct breasts: case report by Neto, Guerino  et al.
  Universidade de São Paulo
 
2012
 
Coexistence of benign phyllodes tumor and
invasive ductal carcinoma in distinct breasts:
case report
 
 
European Journal of Medical Research, London, v.17, p.1-4, 2012
http://www.producao.usp.br/handle/BDPI/34997
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Outros departamentos - FSP/Outros Artigos e Materiais de Revistas Científicas - FSP/Outros
CASE REPORT Open Access
Coexistence of benign phyllodes tumor and
invasive ductal carcinoma in distinct breasts: case
report
Guerino Barbalaco Neto1, Claudia Rossetti1, Natalia A Souza1, Fernando LA Fonseca1, Ligia Ajaime Azzalis2,
Virginia Berlanga Campos Junqueira2, Vitor E Valenti4 and Luiz Carlos de Abreu3*
Abstract
This report describes a rare case of coexistence of benign phyllodes tumor, which measured 9 cm in the right
breast, and invasive ductal carcinoma of 6 cm in the left breast, synchronous and independent, in a 66-year-old
patient. The patient underwent a bilateral mastectomy due to the size of both lesions. Such situations are rare and
usually refer to the occurrence of ductal or lobular carcinoma in situ when associated with malignant phyllodes
tumors, and more often in ipsilateral breast or intra-lesional.
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Background
Phyllodes tumors represent a rare biphasic neoplasm com-
posed of epithelial and stromal elements, which corre-
sponds to a total of 1% of breast cancers and around 2% to
3% of fibroepithelial tumors [1,2]. The concomitance of
these tumors with epithelial malignant neoplasms is rare.
The literature reported the association of phyllodes tumors
with malignant epithelial components mainly in the form
of ductal or lobular in situ lesions and less often in the
invasive form. However, they are usually situated inside
the lesion or near the fibroepithelial neoplasm tissue [3].
Treatment of these tumors depends on the epithelial
and fibroepithelial lesion intrinsic profile. Excision of the
lesion with margins is considered to be adequate in benign
phyllodes tumors cases. On the other hand, when the
phyllodes tumors are large, a simple mastectomy is recom-
mended. In the case of epithelial injury, size, location and
lymph node involvement are not considered in determin-
ing therapeutic approaches [3-5].
Carcinoma is the medical term for the most common
type of cancer occurring in humans [6-8]. The synchron-
ous coexistence of benign phyllodes tumor in one breast
and invasive carcinoma in the other breast is rare. In
fact, we found no reports in the literature documenting
the association of phyllodes tumor and invasive ductal
carcinoma. To our knowledge, this is the first report to
describe a case of synchronous coexistence of benign
phyllodes tumor and invasive ductal carcinoma in dis-
tinct breasts.
Case presentation
This is a 66-year-old patient, with four pregnancies,
three normal deliveries and one abortion. She smoked
from the ages of 10 to 51 years and had no family history
of breast carcinoma. She reported the presence of pro-
gressively growing nodules in both breasts in 2005. In
2006, she underwent a mammography (Figure 1) with
suspicious findings and was referred to the hospital. She
did not visit the hospital for fear of a positive diagnosis.
In December 2006, she underwent another mammog-
raphy, and was examined again in February 2007. Mam-
mography showed a regular 9-cm nodule in the right
breast, without skin retraction, with elastic firm consistency,
diffuse bulging breast and negative axillary lymph nodes.
Mammography also noted a 6-cm nodule in the left breast
with bulging and skin retraction located in inter-medial
quadrants and retro areolar region, hardened, partially
mobile and negative axillary lymph nodes. She was re-
ferred to preoperative assessment and surgery. Incisional
biopsies of both breasts were performed. Biopsy of the left
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breast revealed the presence of invasive ductal carcinoma
(pT3pn0, pMx), Nottingham grade II, nuclear grade III.
Biopsy of the right breast showed a probable benign
phyllodes tumor. No core needle biopsy was performed
because the technology was not available in our clinic.
Based on the diagnosis and the size and location of the
lesions, we decided to perform a simple mastectomy in
the right breast and modified Madden mastectomy in
the left breast.
The anatomopathological final result showed the presence
of benign phyllodes tumor in the right breast (Figure 2),
which measured 9 cm in its longest axis, and invasive ductal
carcinoma Nottingham grade II, nuclear grade III, which
measured 7×6 cm in the left breast. Further evaluation
indicated negative axillary lymph nodes and absence of
metastasis (Figure 3).
For histological assessment, fragments were dipped in
Gender liquid at 4°C for 24 h and were cut into small
pieces of 1 mm3 and post-fixed in a 1% OsO4 solution for
2 h, dehydrated and embedded in araldite. Silver or gray
thin sections (60 to 90 nm) were selected on a Porter-Blum
MT-B ultramicrotome. The ultra-slices were mounted on
copper silver grids with 200 patches and stained with ur-
anyl acetate and lead citrate. The fragments were fixed in
formaldehyde 10% at 4°C. Approximately 24 h later the
fragments were cut in cryostat. This protocol followed the
routine procedures of our laboratory [9-11].
Figure 4 shows the histological evaluation of the of
phyllodes tumor. Figure 5 shows the histological results
of the carcinoma in the left breast focusing on steroid
Her-2/neu-receptor. Preoperatively, history and physical
exam were normal; bilateral mammography, abdominal
Figure 1 “Mammographic examination of the patient. Left 2006,
1 year later.
Figure 2 Anatomopathological results of phyllodes tumor.
Figure 3 Anatomopathological results of the carcinoma in the
left breast.
Figure 4 Histological results of phyllodes tumor.
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and pelvic computed tomography (CT), usg total abdominal
and pelvic, chest imaging, and biochemical tests (complete
blood count, platelets, liver function tests, and alkaline
phosphatase) were all normal. However, bone scan indi-
cated a low probability metastases.
The patient was given adjuvant therapy composed of
radiotherapy and chemotherapy for phyllodes tumor and
carcinoma, respectively. Chemotherapy included six cycles
of the FAC regimen (5-fluorouacil, doxorubicin, dyclopho-
sphamide). To date, the patient has not shown any clinical
or laboratory alterations.
Discussion
Phyllodes tumor of the breast is classified in the literature
as benign, borderline, or malignant subtypes based on fea-
tures of the tumor such as necrosis, margins (pushing or
infiltrative), cellular atypia, stromal overgrowth, and the
number of mitoses per high power field [12,13]. Phyllodes
tumors usually occur in women over 45 years of age, but
may be present at any age, including in children [1]. Char-
acteristics of the tumor which should be considered in
evaluating its behavior and seriousness and to determine
the proper treatment approach include: stroma profile,
stromal cell atypia, growth pattern (heterologous or hom-
ologous), lesion borders (well demarcated or infiltrative),
and presence or absence of necrosis [14]. For example,
Mitotic activity lower than 5 per 10 high power fields
suggests a benign behavior. Mitotic activity rates above
10 per 10 fields indicate potentially malignant behavior
[15]. However, one criterion should never be evaluated
independent of other criteria. Moreover, while a vast
majority of these lesions present with benign features,
approximately 30% exhibit malignancy stromal criteria
[16]. Metastasis is usually hematogenous, described in
around 13% in 10 years for malignant phyllodes tumors.
Thus, axillary dissection is generally not recommended.
Local recurrence is common even in benign forms, and
was observed in more than 8% of cases in 10 years. Local
recurrence is more common in borderline and malig-
nant forms [17].
To our knowledge, this is the first report of a case of
coexisting benign phyllodes tumor and invasive ductal
carcinoma in distinct breasts. The association of carcin-
oma and phyllodes in situ tumor is rare. It has been
reported that 81% of cases represent lobular in situ carcin-
oma, usually with intra-lesional location or on its adja-
cency. Around 33 such cases have been described in the
literature. Other subtypes of cancer associated with phyl-
lodes are related to tubular and squamous carcinoma [18].
The prognosis of carcinoma cases originating from phyl-
lodes is generally favorable [18].
Synchronous and independent lesions in separate breasts
have not been reported, especially benign phyllodes tumor,
not associated with adjacent invasive lesions or intra-
lesions. Some authors recommend treating phyllodes
tumors based on their carcinomatous features [18]. In
our case, we performed incisional biopsies of both breasts.
As an adjuvant therapy, we administrated chemotherapy
and radiotherapy for carcinoma and phyllodes tumor,
respectively. With respect to phyllodes tumor, usually,
surgical treatment alone is adequate. Some units pro-
posed adjuvant chemo and radiotherapy in certain cases
(recurrent phyllodes tumor after mastectomy, stromal
overgrowth), but the role of adjuvant treatments is not
yet clear. The treatment of phyllodes tumors depends
fundamentally on surgery in the breast. A wide excision
of the tumor with a 10-mm clear margin is recom-
mended [19]; mastectomy is recommended if breast
conservation surgery is not possible. Shelling out of
tumors is not adequate, but frequently done because of
the similitude with fibroadenomas and the difficulties of
preoperative histological diagnosis [20].
Conservative surgery with excision margins (about 1 cm)
showed a good prognosis for benign phyllodes with recur-
rence rates that range from 8% to 20% with no risk of
metastasis. However, treatment noncompliance by patients,
as reported in this case, is an important concern In this
case, the choice of mastectomy became inevitable due to
the large scale of the two lesions, a fact which unfortunately,
also contributed to a poor prognosis.
Little is known about the genetic abnormalities in phyl-
lodes. We could speculate that there is a genetic relation-
ship between the two both lesions. Although oncogene
activation and tumor suppressor gene inactivation are
important mechanisms in the genesis, propagation, and
spread of most cancers, the role of these processes in
phyllodes tumor has not been previously explored. It is
well known that allelic loss is a common early genetic
alteration during tumorogenesis [21].
Figure 5 Histological results of the carcinoma in the left breast.
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Conclusions
The association of phyllodes tumor with breast carcin-
omas is rare, especially in the form of synchronous and
independent lesions in separate breasts. We reported the
first case of the coexistence of benign phyllodes tumor
and synchronous, independent and invasive ductal car-
cinoma in separate breasts.
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